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Abstract
Plasmodium falciparum malaria (Pf-malaria) and Epstein Barr Virus (EBV) infections coexist in children at risk for endemic
Burkitt’s lymphoma (eBL); yet studies have only glimpsed the cumulative effect of Pf-malaria on EBV-specific immunity.
Using pooled EBV lytic and latent CD8+ T-cell epitope-peptides, IFN-c ELISPOT responses were surveyed three times among
children (10 months to 15 years) in Kenya from 2002–2004. Prevalence ratios (PR) and 95% confidence intervals (CI) were
estimated in association with Pf-malaria exposure, defined at the district-level (Kisumu: holoendemic; Nandi: hypoendemic)
and the individual-level. We observed a 46% decrease in positive EBV lytic antigen IFN-c responses among 5–9 year olds
residing in Kisumu compared to Nandi (PR: 0.54; 95% CI: 0.30–0.99). Individual-level analysis in Kisumu revealed further
impairment of EBV lytic antigen responses among 5–9 year olds consistently infected with Pf-malaria compared to those
never infected. There were no observed district- or individual-level differences between Pf-malaria exposure and EBV latent
antigen IFN-c response. The gradual decrease of EBV lytic antigen but not latent antigen IFN-c responses after primary
infection suggests a specific loss in immunological control over the lytic cycle in children residing in malaria holoendemic
areas, further refining our understanding of eBL etiology.
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Introduction
Plasmodium falciparum (Pf) malaria and Epstein Barr Virus (EBV)
have been identified as co-factors in the pathogenesis of endemic
Burkitt’s lymphoma (eBL) [1] which is estimated to account for
70% of cancers among children in equatorial Africa [2,3]. In areas
with intense perennial malaria transmission (holoendemic), the
highest incidence of eBL is in children aged 4–8 years
[4,5,6,7,8,9], in contrast to areas with low malaria transmission
(hypoendemic) where eBL is rarely reported [7,10,11].
It has been hypothesized that Pf-malaria infections promote eBL
in two mutually-compatible ways. In developing countries, most
children experience primary EBV infection by 3 years of age,
followed by life-long infection in memory B-lymphocytes [12,13].
P. falciparum induces polyclonal B-cell expansion and lytic EBV
reactivation [14], thus increasing the number of latently-infected
B-cells. In otherwise healthy individuals, interferon-gamma (IFN-
c) secreting cytotoxic CD8+ T-cells mediate immunosurveillance
of EBV [5,12,15,16,17,18]. Repeated Pf-malaria infections could
hence lead to exhaustion or hypo-responsiveness of EBV latent or
lytic antigen CD8+ T-cells, thus increasing the chance for this
EBV-associated malignancy to arise.
Limited evidence supports an impaired EBV-specific T-cell
response in association with Pf-malaria. Using an in vitro
regression assay as a measure of cytotoxicity, children with acute
Pf-malaria demonstrated a transient loss of control over B-cell
outgrowth [19,20,21]. Furthermore, case-control studies compar-
ing acutely Pf-malaria infected individuals with healthy adults
came to the same conclusion [22,23]. However, the cumulative
effect of repeated often asymptomatic Pf-malaria infections on
EBV persistence has not been thoroughly studied [1,6,24,25]. Two
ecological studies provide the minimum understanding we have on
the relationship. A study among adults found a loss of EBV-
specific T-cell control among those exposed to holoendemic
compared to hypoendemic malaria [26]. A second study only
found significantly lower EBV latent and lytic antigen IFN-c
responses in children 5–9 years old residing in the holoendemic
area compared to other age groups and children from a
hypoendemic area [16].
The objective of this study was to examine the influence
of cumulative Pf-malaria on EBV latent and lytic antigen
CD8+ T-cell IFN-c ELISPOT responses in children over a two-
year period.
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Results
Participant summary
Of the 236 children enrolled, 230 (97.5%) were seropositive for
EBV [27]. Our weighted analysis included 149 children who
participated in all surveys and had interpretable EBV-specific T-
cell responses (Table 1). The age and sex distribution between the
districts were not significantly different (P= .11 and P= .30,
respectively). Children in Kisumu experienced more Pf-malaria
infections than children in Nandi (P,.001); only 3% of Kisumu
children were never infected compared to 78% in Nandi. This was
despite a classically defined malaria outbreak in Nandi during the
survey periods (Figure 1).
The magnitude of EBV-specific IFN-c responses did not
differ significantly by malaria endemicity. The proportion
of positive IFN-c responses to PHA (positive control) demonstrates
that children from both districts were equally able to elicit an IFN-
c response indicating no global signs of immune dysfunction
(Table 2). There were no significant differences in median values
of EBV lytic or latent CD8+ T-cell IFN-c responses between
children of similar age groups across districts. Therefore, Pf-
malaria exposure does not appear to influence the magnitude of
EBV-specific IFN-c responses.
Pf-malaria exposure (district-level) and EBV-specific T-cell
IFN-c responses
EBV lytic antigen CD8+ T-cell IFN-c responses. We
observed a few intriguing patterns in the prevalence of positive
EBV lytic antigen CD8+ T-cell IFN-c response when children
were stratified into age groups by their baseline age (age group
cohorts) (Figure 2A,C). In Kisumu, the prevalence of positive
Figure 1. Malaria incidence in the highland area of Kipsamoite, 2001–2004.
doi:10.1371/journal.pone.0031753.g001
Table 1. Summary of participants in the Kisumu/Nandi
cohort, Kenya 2002–2004a.
Site Total
Kisumu
(holoendemic)
Nandi
(hypoendemic)
n % n %
Sex
Male 39 59.1 38 45.8 77
Female 27 40.9 45 54.2 72
Age (in years)
0–4 16 24.2 30 36.1 46
5–9 33 50.0 35 42.2 68
$10 17 25.8 18 21.7 35
Malaria infections
All surveys 38 57.6 0 0 38
Two surveys 20 30.3 4 4.8 24
One survey 6 9.1 14 16.9 20
Never 2 3.0 65 78.3 67
Total 66 83 149
n, number; %, percentage.
aData in the table are weighted according to the 149 children who participated
in all surveys and had interpretable Epstein-Barr virus (EBV) specific CD8+ T-cell
IFN-c response.
doi:10.1371/journal.pone.0031753.t001
Malaria and EBV-Specific T-Cell Immunity
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e31753
responses in the 0–4 year and 5–9 year cohorts decreased from
baseline to first follow-up, but remained unchanged in the $10
year cohort. By the second follow-up, responses increased among
the 0–4 and 5–9 year cohorts while responses decreased in $10
year cohort. However, children in the 5–9 year cohort had the
lowest prevalence at each survey period. In Nandi, responses
declined in all age group cohorts from baseline to first follow-up
and remained almost unchanged in the 5–9 year and $10 year
cohorts by the second follow-up. In the 0–4 year cohort, however,
responses increased. The patterns and prevalence of responses
among the age group cohorts were similar at all survey periods,
varying ,10%.
Using the district-level definition of Pf-malaria and the weighted
model, we estimated the prevalence of positive responses in
Kisumu was 0.70 (95% CI: 0.45–1.08) times the prevalence in
Nandi although this 30% difference was not significant. In
Kisumu, there were no significant differences in positive responses
in children 0–4 years (PR: 1.39, 95% CI: 0.60–3.20) and 5–9 years
(PR: 0.74, 95% CI: 0.37–1.48) when compared to children $10
years (Figure 3A). Likewise in Nandi, the prevalence of positive
responses in children 0–4 years (PR: 1.10, 95% CI: 0.60–2.02) and
5–9 years (PR: 1.04, 95% CI: 0.61–1.76) did not differ significantly
from children $10 years. When similar age groups were
compared between districts, we detected a significant difference
in children 5–9 years where the prevalence of positive responses in
Kisumu was 0.54 (95% CI: 0.30–0.99) that of children in Nandi
(Figure 3A). No other differences by age group were found.
EBV latent antigen CD8+ T-cell IFN-c responses. Examining
the patterns in the prevalence of positive EBV latent antigen CD8+ T-
cell IFN-c response by age group cohorts, there was variation within
and between districts (Figure 2B,D). In Kisumu, the prevalence at
baseline was highest among the 0–4 year cohort but then decreased to
nearly the same prevalence as the other age group cohorts. In Nandi,
there was a decreasing trend from baseline to second follow-up for the
Table 2. EBV-specific CD8+ T-cell IFN-c Response by Residence and Age Groupa.
EBV lytic antigens EBV latent antigens PHAb
n % Medianc n % Medianc n %
(range) (range)
Baseline (July–August 2002)
Kisumu
0–4 years 7/16 43.8 96 (14–166) 8/16 50.0 43 (20–98) 13/16 81.3
5–9 years 8/33 24.2 67 (18–170) 6/33 18.2 47 (16–448) 31/33 93.9
$10 years 5/17 29.4 150 (20–350) 5/17 29.4 46 (16–404) 15/17 88.2
Nandi
0–4 years 12/30 34.3 98 (28–836) 8/30 26.7 70 (18–146) 28/30 93.3
5–9 years 15/35 42.9 50 (22–792) 11/35 31.4 84 (42–668) 33/35 94.3
$10 years 8/18 22.9 53 (36–304) 8/18 44.4 88 (26–1322) 18/18 100
First follow-up (February–March 2003)
Kisumu
0–4 years 4/16 25.0 46 (40–128) 2/16 12.5 55 (32–78) 16/16 100
5–9 years 1/33 3.0 20 (20) 6/33 18.2 15 (14–132) 31/33 93.9
$10 years 5/17 29.4 30 (18–162) 2/17 11.8 23 (18–28) 16/17 94.1
Nandi
0–4 years 6/30 20.0 98 (24–744) 4/30 13.3 77 (32–128) 26/30 86.7
5–9 years 8/35 22.9 82 (16–1742) 8/35 22.9 58 (20–248) 34/35 97.1
$10 years 5/18 27.8 54 (32–382) 3/18 16.7 54 (14–354) 18/18 100
Second follow-up (July–August 2004)
Kisumu
0–4 years 5/16 31.3 76 (30–84) 2/16 12.5 106 (64–148) 15/16 93.8
5–9 years 3/33 9.1 60 (56–150) 3/33 9.1 42 (24–74) 33/33 100
$10 years 3/17 17.7 250 (40–288) 1/17 5.9 16 (16) 17/17 100
Nandi
0–4 years 8/30 26.7 50 (14–384) 2/30 6.7 69 (58–80) 25/30 83.3
5–9 years 7/35 20.0 76 (14–278) 6/35 17.1 59 (14–214) 31/35 88.6
$10 years 5/18 27.8 26 (14–130) 5/18 27.8 56 (22–122) 18/18 100
n, number; %, percentage; EBV, Epstein-Barr Virus; PHA, Phytohemagglutinin.
aData in the table are weighted according to the 149 children who participated in all surveys and had interpretable Epstein-Barr Virus (EBV) specific CD8+ T-cell IFN-c
response.
bPhytohemagglutinin (PHA) was used as a positive control.
cMedian EBV-specific CD8+ T-cell IFN-c responses were calculated among children with positive responses and is expressed as spot forming units (SFU) per 16106
peripheral blood mononuclear cells (PBMC).
doi:10.1371/journal.pone.0031753.t002
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0–4 year and 5–9 year cohorts. However, the$10 years cohort had the
highest prevalence of response at baseline that decreased by the first
follow-up but rebounded by the second follow-up.
From our weighted model, we observed the prevalence of
positive responses in Kisumu was 0.80 (95% CI: 0.51–1.25) times
the prevalence in Nandi, although not significant. In Kisumu, the
prevalence of positive responses in children 0–4 years (PR: 1.93,
95% CI: 0.91–4.13) and 5–9 years (PR: 1.22, 95% CI: 0.61–2.45)
was not significantly different from children $10 years, although
there was a decrease in prevalence with increasing age group
(Figure 3B). Similarly in Nandi, responses among children 0–4
years (PR: 0.72, 95% CI: 0.35–1.48) and 5–9 years (PR: 0.84, 95%
CI: 0.47–1.49) did not differ significantly from children $10 years
old, although there was a slight increase in response with
increasing age. Despite these interesting trends, there were no
significant differences in the prevalence of positive responses when
similar age groups were compared between districts.
Pf-malaria infection (individual-level) and EBV-specific T-
cell IFN-c responses
EBV lytic antigen CD8+ T-cell IFN-c responses. Using the
individual-level definition of Pf-malaria in our weighted model, we
found the association between recurrent Pf-malaria infections and
EBV lytic antigen CD8+ T-cell IFN-c response varied by age
group and survey period. We therefore used two weighted models.
In the first model, we stratified results by age group, while
adjusting for sex and survey period. Similarly in the second model,
we stratified by survey period while adjusting for sex and age
group.
We noted three observations from our analysis. First, the PR of
recurrent Pf-malaria infections and positive IFN-c responses
among Kisumu children were consistently lower than Nandi
children for all age groups and survey periods (Table 3). In
general, there is a two-fold difference in the PR between Kisumu
and Nandi although not significant (P= .32). Secondly, the
association between recurrent Pf-malaria infections and IFN-c
responses varied by age group. In both Kisumu and Nandi, the
prevalence of positive responses among children 0–4 years with
recurrent Pf-malaria infections was higher than that of similarly
aged children never infected. In Nandi, the difference was
statistically significant. Finally, the PR of recurrent Pf-malaria
infections and IFN-c responses to EBV lytic antigens varied by
survey period in both districts. At baseline, for both districts, the
PR of positive responses among children with recurrent Pf-malaria
Figure 2. Change in prevalence of EBV-specific CD8+ T-cell IFNc responses with age. Changes in prevalence of positive EBV lytic (A and C)
and latent (B and D) antigen CD8+ T-cell IFNc response from 2002–2004. Age group at each survey period is based on age at baseline. In Kisumu: 16
(0–4 years), 33 (5–9 years) and 17 ($10 years). In Nandi: 30 (0–4 years), 35 (5–9 years) and 18 ($10 years). Solid black line: 0–4 year olds; hash-mark
green line: 5–9 year olds; and dotted blue line: $10 year old children.
doi:10.1371/journal.pone.0031753.g002
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infections was greater compared to children never infected; this
result was statistically significant in Nandi, but not Kisumu.
However, the PR decreased at subsequent study periods; the
prevalence of positive responses among children with recurrent
Pf-malaria infection diminished over time compared to children
never infected. This could reflect functional diminishment of
responsive EBV lytic antigen T-cells under continuous pressure
from Pf-malaria.
Figure 3. Prevalence of EBV-specific CD8+ T-cell IFNc response by age group and residence. Prevalence of positive EBV lytic (A) and latent
(B) antigen CD8+ T-cell IFNc response by age group and site of residence, Kenya 2002–2004. Age group was classified as a time-varying factor. For
both graphs, the number of observations for children in each age group in Kisumu was: 33 (0–4 years), 87 (5–9 years) and 78 ($10 years). The number
of observations for children in each age group in Nandi was: 54 (0–4 years), 125 (5–9 years) and 70 ($10 years). P values for differences between areas
of residence by age group are indicated.
doi:10.1371/journal.pone.0031753.g003
Table 3. Prevalence Ratios for EBV Lytic Antigen CD8+ T-cell IFN-c Response.
Kisumu Nandi
Constant Pf-malaria infection versus no infection Constant Pf-malaria infection versus no infection
PR 95% CI PR 95% CI
Unadjusted 0.64 0.23–1.77 1.43 0.73–2.81
Age groupsa
0–4 years 1.31 0.28–6.18 3.00 1.72–5.23
5–9 years 0.53 0.15–1.88 1.16 0.39–3.45
$10 years 0.78 0.16–3.53 0.98 0.33–2.95
Survey periodsb
Baseline 1.24 0.49–3.11 1.76 1.07–2.91
Six months 0.29 0.05–1.62 0.73 0.17–3.22
Two years 0.21 0.05–0.92 0.22 0.02–3.23
Pf-malaria, Plasmodium falciparum malaria; EBV, Epstein-Barr virus; PR, prevalence ratio; CI, confidence interval; Ref, referent group.
aAdjusted for sex and survey period. Unstratified estimates for constant Pf-malaria infections compared to never infected in Kisumu (P= 0.72) and Nandi (P=0.97) were
not significant. Specific details on the number and prevalence of positive responses for each age group are included in Table 2.
bAdjusted for sex and age group. Unstratified estimates for constant Pf-malaria infections compared to never infected was not significant in Kisumu (P= 0.65) but
significant in Nandi (P=0.03). The number of children in Kisumu for each survey period was 66 and the number of children in Nandi was 83.
doi:10.1371/journal.pone.0031753.t003
Malaria and EBV-Specific T-Cell Immunity
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EBV latent antigen CD8+ T-cell IFN-c responses. Using
our weighted model, we did not observe any variation by age
group (Table 4) or survey period (data not shown). In Kisumu, for
all age groups, the adjusted prevalence of positive EBV latent
antigen CD8+ T-cell IFN-c response was higher among children
with recurrent Pf-malaria infections compared to those never
infected (Table 4). There was a two-fold difference in the PR for
children 0–4 years and .10 years with recurrent Pf-malaria
infections than children 5–9 years. In Nandi, children 0–4 years
with recurrent Pf-malaria infections had fewer positive responses
than children never infected, and a PR that was three-fold lower
than older children. However, children in older age groups with
recurrent Pf-malaria infections had higher positive responses than
similarly aged children never infected. Despite estimates for
Kisumu and Nandi being imprecise and not statistically significant,
the observations suggest that children 5–9 years in Kisumu are
unable to mount the type of T-cell response as younger and older
children. Meanwhile, in Nandi, the increasing PR with age may
reflect how a maturing immune system, not continuously exposed
to Pf-malaria, is able to induce a T-cell response to latent antigens
even when co-infected with Pf-malaria.
Discussion
Our study demonstrates that the prevalence of positive EBV lytic-
but not latent-antigen CD8+ T-cell IFN-c responses decreases in a
malaria holoendemic area and not a hypoendemic area. This
suggests that children repeatedly infected with Pf-malaria eventually
lose functional IFN-c producing CD8+ T-cells in response to EBV
lytic antigens. In an effort to control viral replication induced by
recurrent Pf-malaria infections [14], we hypothesize that EBV lytic
antigen CD8+ T-cells have become exhausted and unable to
produce IFN-c or alternatively these cells were culled through
apoptosis. As a result of the loss of responsive EBV lytic antigen
CD8+ T-cells, more B-lymphocytes could become latently infected
by EBV, and thus gradually increasing the risk of eBL. These
findings are consistent with previous studies of this cohort, which
detected significantly higher median EBV viral load and EBV-
specific IgG antibodies to EBV lytic and latent antigens in the
holoendemic compared to hypoendemic area [27,28].
Furthermore, the association between Pf-malaria infections and
positive EBV lytic antigen CD8+ T-cell IFN-c responses varied by
age group. The EBV lytic antigen deficiency was most pronounced
among children 5–9 years old in the malaria holoendemic area
and was further potentiated in those recurrently infected with
Pf-malaria. In our individual-level analysis, these children had the
lowest PR of positive responses while this same age group in the
hypoendemic area appeared to be affected little. Additionally, the
patterns observed in the age group cohorts clearly showed that the
5–9 year cohort in Kisumu had the lowest prevalence of positive
responses among all age group cohorts, in both districts, at each
survey period. The sustained inability to produce an effective EBV
lytic antigen CD8+ T-cell IFN-c response among 5–9 year olds
may be an etiologically relevant event in eBL development since
eBL is most often diagnosed in this age group. Finally, the
inconsistency of patterns between age group cohorts within a
district suggests there is an age-dependent interaction between Pf-
malaria and EBV-specific T-cell response. Studies of immune
mechanisms that induce exhaustion or deletion are needed to
understand maintenance of EBV-specific T-cell immunity,
especially in children. In support of this premise is the observation
that the ELISPOT responses in both groups of children were
lower than those described for healthy adults [29] and our Kenyan
adult controls (data not shown). To our knowledge there have
been no studies of EBV-specific T-cell immunity in healthy
children from non-malaria endemic countries. However our
studies of malaria-specific immunity also demonstrate an age-
associated instability in cytokine recall responses more pronounced
in children compared to adults [30,31].
This study is an important early step to understanding the
cumulative effect of Pf-malaria infections on EBV-specific T-cell
immunity over time. Availability of data over two-years permitted
identification of potentially important biological and environmen-
tal mechanisms that only became apparent over time. For
example, the association between Pf-malaria infection and positive
EBV lytic antigen CD8+ T-cell IFN-c responses varied by age
group and survey period. The variation noted with age group is
expected because there is an age-dependent increase in T-cell
immunity as children develop protection against Pf-malaria after
repeated infections [32]. Children in malaria holoendemic areas
acquire immunity to Pf-malaria and EBV during the first years of
life, and ongoing studies will compare the development of Pf-
malaria to EBV-specific T-cell memory. An impairment of EBV-
specific T-cell control with progressive EBV reactivation has been
described in HIV-infected individuals [33], lending support to a
sequential series of events in the etiology of eBL.
Using data, collected during a two-year period, also allowed us
to use an individual-level definition for Pf-malaria infections.
Unlike other studies, our definition accounted for the cumulative
effect of Pf-malaria infection which has been hypothesized to be
critical in the pathogenesis of eBL, rather than the transient effect
Table 4. Prevalence Ratio for EBV Latent Antigen CD8+ T-cell IFN-c Response.
Kisumu Nandi
Constant Pf-malaria infection versus no infection Constant Pf-malaria infection versus no infection
PR 95% CI PR 95% CI
Unadjusted 1.60 0.37–6.92 1.54 0.71–3.35
Age groupsa
0–4 years 2.10 0.22–19.65 0.51 0.08–3.37
5–9 years 1.14 0.26–4.99 1.47 0.58–3.63
$10 years 2.68 0.38–18.73 1.82 0.83–3.99
Pf-malaria, Plasmodium falciparum malaria; EBV, Epstein - Barr virus; PR, prevalence ratio; CI, confidence interval.
aAdjusted for sex and survey period. Unstratified estimates for constant Pf-malaria infections compared to never infected in Kisumu (P= 0.32) and Nandi (P=0.13) were
not significant. Specific details on the number and prevalence of positive responses for each age group are included in Table 2.
doi:10.1371/journal.pone.0031753.t004
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typically observed with acute Pf-malaria infection [1]. However,
our definition was vulnerable to misclassification because Pf-
malaria infection was assessed only twice during the two-year
follow-up. Therefore, we may not have captured participants’
malaria histories accurately. This misclassification was likely to be
differential because children in the holoendemic area were
exposed to Pf-malaria parasites at a higher frequency, averaging
two malaria infections per year, than children in the hypoendemic
area [34]. Therefore, we may have underestimated or overesti-
mated the PR for Pf-malaria infections and EBV-specific T-cell
responses in the holoendemic area.
A strength of our study was the use of two definitions for Pf-
malaria: 1) district-level according to malaria transmission intensity,
and 2) individual-level based on measured Pf-malaria infection.
Although our findings of EBV lytic antigen CD8+ T-cell IFN-c
responses were consistent with both definitions, our findings of EBV
latent antigen CD8+ T-cell IFN-c responses were inconsistent. This
may have been due to the limited power or an underestimation of
the influence of Pf-malaria infections in hypoendemic areas.
However, it also highlights the potential pitfall in attributing
district-level results to the individual, also known as the ecological
fallacy. The inconsistency may have been due to other factors that
differed between the districts and unrelated to malaria transmission
intensities. Therefore, we conclude that the use of malaria
transmission intensity as a surrogate for malaria infection has been
informative yet future studies should endeavor to prospectively
collect Pf-malaria and EBV co-infections information from
individuals to more accurately describe this complex relationship.
There were several potential confounders that were not captured
in our study, specifically HIV status, nutritional status, schistoso-
miasis infection, and socioeconomic status. However, we do not
believe the absence of these confounders materially affected our
findings. When data were collected in western Kenya from 2002–
2004, HIV testing in infants was conducted only when medically
warranted. All children enrolled in this study were examined by a
clinician and had no obvious signs of illness or malnourishment, and
no deaths were reported as of 2009. Therefore, even though it was
possible that an underlying HIV infection might influence the rate
of malaria parasitaemia [35] the likelihood that a significant number
of undiagnosed children remained in this study was low.
Schistosomiasis infection was unmeasured yet an examination of
the Pf-malaria and EBV response relationship indicated adjusting
for schistosomiasis infection would have biased our analysis. Finally,
is socioeconomic status had been measures, participants and their
families would likely have been classified as low socioeconomic
status because the main occupation was fishing (Kisumu) and
farming (Nandi) in both rural study areas with homes constructed of
locally available materials.
Our findings on EBV lytic antigen CD8+ T-cell IFN-c
responses were consistent with the studies that have used residence
area (malaria transmission intensity) to explore the cumulative
effect of Pf-malaria infections on EBV-specific T-cell response. We
observed fewer positive EBV lytic antigen CD8+ T-cell IFN-c
responses among 5–9 year old than older children [16]. We also
identified a reduction in EBV-specific T-cell response among
children living in a holoendemic compared a hypoendemic area
[26]. The consistency of our findings with previous studies is
important given our limited sample size and precision. Meanwhile,
our analysis of EBV lytic antigen CD8+ T-cell IFN-c response at
the individual-level supports findings from previous studies that
used residence area as a surrogate for Pf-malaria infection.
However, we did not detect the same statistically significant
district-level difference in positive EBV latent antigen CD8+ T-cell
IFN-c responses among 5–9 year olds as a previous study [16].
This discrepancy may be due to the limited power of our study.
Furthermore, the difference between our individual-level analysis
and the previous study may also be due to the use of a surrogate
definition of Pf-malaria.
This study design marks a step toward examining the individual-
level association of Pf-malaria infections and EBV-specific T-cell
IFN-c responses and identifies a potential difference between
children recurrently infected with Pf-malaria compared to children
never infected. To adequately quantify this effect, a longitudinal
study should be considered which could accurately measure Pf-
malaria infection and changes in Pf-malaria and EBV-specific T-cell
immunity over time. The temporal aspects of future studies will be
vital to elucidating the precise mechanism by which repeated Pf-
malaria infections affect EBV persistence and immunity.
Materials and Methods
The Kisumu/Nandi cohort has been previously described [27]. In
brief, the cohort consists of 236 children, randomly selected and
between 10 months and 15 years at enrollment, from two districts in
western Kenya with disparate Pf-malaria transmission intensities:
Kisumu is characterized as holoendemic and Nandi as hypoendemic.
Due to the age-related incidence of eBL, an equal distribution of
children by age and sex were enrolled from each area: children 0–4
years have an elevated risk of eBL whereas 5–9 year olds are at highest
risk and$10 years old have the lowest risk. Data were collected from
2002–2004 using a standardized survey. Three face-to-face interviews
were conducted at baseline (July–August 2002), six month follow-up
(February–March 2003), and two-year follow-up (July–August 2004).
Blood was also collected for malaria and EBV testing.
Pf-malaria infection was confirmed on thick and thin blood
smears by microscopy. Testing of EBV-specific T-cell response by
IFN-c ELISPOT has been previously described [16]. Lytic (BRLF1,
BZLF1, and BMLF1) and latent (Epstein-Barr nuclear antigen
[EBNA] 3A, EBNA 3B, and EBNA3C) antigens were selected and
pooled for testing. One positive control (mitogen phytohemmag-
glutinin [PHA]) was used to stimulate wells and a negative control
(phosphate buffer saline [PBS]) was used to measure background
IFN-c response in unstimulated wells. Assays were condensed into a
three-week period using the same reagents and personnel to
minimize inter-assay variability. Cytotoxic T-lymphocyte (CTL)
ImmunoSpot scanning and imaging software (version 4; Cellular
Technology Ltd, Shaker Heights, OH) was used to count the
number of spot-forming units (SFU) per well; results were expressed
as SFU per million peripheral blood mononuclear cells (PBMC).
Using a two-sided Fisher’s exact test (P,.05), EBV lytic and latent
epitope-peptide CD8+ T-cell IFN-c responses were categorized as
positive or negative. A positive response was recorded if the
proportion of SFUs in the stimulated well was significantly different
from the proportion of SFU in the unstimulated well. The
magnitude of response was calculated by subtracting the SFU in
PBS wells (negative control) from the SFU in the stimulated wells.
The median value for the negative control wells was 4 SFU per
million PBMCs (range 0 to 772 SFU/million PBMC). Median
values were calculated among positive responders only.
Analyses were restricted to EBV seropositive children at
baseline [27]. We used two definitions of cumulative Pf-malaria.
First, Pf-malaria exposure was defined according to the malaria
transmission intensity of the district (district-level definition):
Kisumu (holoendemic) or Nandi (hypoendemic). Next, Pf-malaria
infection was defined as the cumulative average of P. falciparum
infection (parasitemia) in a participant over the three survey
periods (individual-level definition). The value ranged from 0
(never infected) to 1 (always infected); results and discussion focus
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on children who were always infected (referred to as recurrent) and
never infected. With the individual-level definition, we also
included the covariates age group, district, sex, and when the
survey was conducted (referred to as survey period) in the analysis.
We first examined covariates as potential effect measure modifiers
using an a priori cutoff of P= .20. In the absence of evidence of
effect measure modification, we included covariates in the model
as potential confounders.
For descriptive analyses, we used the Chi-square statistic to
measure associations between categorical exposures and outcomes.
We used the two-sided Wilcoxon rank sum (Mann-Whitney U)/
Kruskal Wallis test for continuous outcomes. For multivariable
analyses, we used weighted log-binomial regression with robust
variances to estimate the prevalence ratios (PR) and corresponding
95% confidence intervals (CI). We used generalized estimating
equations (GEE) with robust variance estimators to account for
correlation due to repeated measurements. A weighted model with
inverse probability weights (IPWs) was used to address missing
observations due to children not participating in all surveys. When
using IPW, observations are assumed to be missing at random;
missing data are dependent on observed data but independent of
unobserved data [36]. To calculate IPWs, the probability of
participation was modeled using available predictor variables. The
inverse of the predicted probabilities were calculated and assigned
to each individual with complete data. Individuals with complete
data were weighted to represent individuals with similar
characteristics who have missing data.
To calculate the predicted probabilities for our study, we used
logistic regression with first order interaction terms using the
following equation:
Log
pi
1{pi
 
~b0zb1(sex)zb2(age group 0{4 years)
zb3(age group 5{9 years)
zb4(site of residence)
zb5(sex|age group 0{4 years)
zb6(sex|age group 5{9 years)
zb7(sex|site of residence)
zb8(age group 0{4 years|site of residence)
zb9(age group 5{9 years|site of residence)
Where pi was the probability of child i (i=1,2,3…n) participating
in all surveys. Taking the inverse of the predicted probabilities, the
mean IPW was 1.44 and ranged from 1.14–1.92. Children who
participated in all three surveys were assigned the mean IPW value
whereas children with missing observations were assigned an IPW
of 0. We also conducted complete case analyses and found no
differences in the PR or 95% CI; therefore we report results from
the weighted analyses. Data were analyzed in SAS 9.1.3 (Cary,
NC).
Written informed consent was obtained from a parent or
guardian of the participant. This study was approved by the
Institutional Review Boards at the University Hospitals of
Cleveland, Case Western Reserve University where Dr. Moor-
mann was affiliated at the time this study was done and also
obtained from the Ethical Review Committee for the Kenya
Medical Research Institute. It was deemed exempt by the
Institutional Review Board at the University of North Carolina
at Chapel Hill.
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